Study of POLE mutation in high-risk endometrial cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial looks at a specific genetic change called POLE mutation in women with endometrial cancer that has a high risk of coming back. It may help doctors understand who could benefit from different treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman diagnosed with endometrial cancer.
- Your cancer is considered high-risk for coming back after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a chemotherapy combination (carboplatin and paclitaxel) plus the immunotherapy drug pembrolizumab, followed by maintenance pembrolizumab either alone or with a PARP inhibitor called nesuparib. It is for women with advanced or recurrent endometrial cancer that is MMR-proficient (a type where the cells have a normal ability to fix DNA).
This trial tests a new study medicine called PF-08634404 when combined with standard chemotherapy for people with advanced or recurrent endometrial cancer that is MMR-proficient (meaning the DNA repair system is working normally). The goal is to see if adding this medicine helps shrink or control the cancer better than chemotherapy alone.
This Phase 2 trial studies an added (adjuvant) treatment for early-stage uterine cancer that has a specific genetic change called POLE mutation and does not have a p53 abnormal pattern. The goal is to lower the risk of the cancer coming back after surgery.
This study looks at women with certain high-risk types of endometrial cancer that have not spread into the muscle wall of the uterus. It aims to understand how these cancers behave and whether lymph node testing is needed, which could help guide treatment decisions.
This trial tests a tailored approach to preserve fertility in women with early-stage endometrial cancer, using medications like hormones and immunotherapy based on the tumor's molecular subtype. It aims to avoid hysterectomy and keep the uterus intact.
This study is testing whether a special kind of medicine called a PARP inhibitor can work against endometrial cancer cells grown in a lab from your tumor. The goal is to find out which patients might benefit from this treatment in the future.
Hear when a new Endometrial Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.